問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of General Internal Medicine

Division of Hematology & Oncology

Division of General Surgery

National Taiwan University Hospital Hsin-Chu Branch

Division of Hematology & Oncology

National Taiwan University Cancer Center

Division of General Internal Medicine

Division of Hematology & Oncology

更新時間：2023-09-19

盧彥伸LU, YEN-SHEN
  • Principal Investigator
  • Clinical Trial Experience (year) 22 years 10 個月

Recruiting Trial

115Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

盧彥伸

List

223Cases

2007-11-01 - 2010-10-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Terminated8Sites

2009-01-01 - 2012-12-31

Phase I/II

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

2009-11-15 - 2019-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2009-01-01 - 2011-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

2017-07-01 - 2020-03-31

Phase II

A Phase II, Open Label, Randomised, Multi-centre Study to Assess the Safety and Efficacy of Agents Targeting DNA Damage Repair in Combination With Olaparib Versus Olaparib Monotherapy in the Treatment of Metastatic Triple Negative Breast Cancer Patients Stratified by Alterations in Homologous Recombinant Repair (HRR)-Related Genes (Including BRCA1/2) (VIOLETTE).

  • Condition/Disease

    Metastatic Triple Negative Breast Cancer

  • Test Drug

    Olaparib (AZD2281), AZD6738 and AZD1775

Participate Sites
10Sites

Terminated9Sites

趙祖怡
Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

Division of General Internal Medicine

陳訓徹
Linkou Chang Gung Medical Foundation

2013-06-01 - 2013-12-31

Others

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

2015-01-15 - 2023-06-06

Phase III

A Phase III randomized, double-blind, placebo-controlled study of LEE011 or placebo in combination with tamoxifen and goserelin or a non-steroidal aromatase inhibitor (NSAI) and goserelin for the treatment of premenopausal women with hormone receptor positive, HER2-negative, advanced breast cancer.

  • Condition/Disease

    hormone receptor positive, HER2-negative, advanced breast cancer.

  • Test Drug

    LEE011

Participate Sites
8Sites

Terminated8Sites

2015-07-10 - 2019-02-12

Phase II

A randomized phase II study of MCS110 combined with carboplatin and gemcitabine in advanced Triple Negative Breast Cancer (TNBC)

  • Condition/Disease

    advanced Triple Negative Breast Cancer (TNBC)

  • Test Drug

    MCS110

Participate Sites
1Sites

Terminated1Sites

2014-04-01 - 2019-12-31

Phase I/II

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

2015-10-01 - 2020-04-30

Phase III

SOLAR-1: A phase III randomized double-blind, placebo controlled study of alpelisib in combination with fulvestrant for men and postmenopausal women with hormone receptor positive, HER2-negative advanced breast cancer which progressed on or after aromatase inhibitor (AI) treatment

  • Condition/Disease

    hormone receptor positive, HER2-negative advanced breast cancer

  • Test Drug

    BYL719/Faslodex

Participate Sites
3Sites

Terminated3Sites

曾令民
Taipei Veterans General Hospital

1 18 19 20 21 22 23
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB